{"doi":"10.1136/rmdopen-2025-006356","title":"Characteristics, treatments and outcomes of patients with dermatomyositis using real-world data","abstract":"<jats:sec>\n                    <jats:title>Objective</jats:title>\n                    <jats:p>Studies of dermatomyositis (DM) are frequently limited to single-centre cohorts. We used two large nationally representative US cohorts to conduct a descriptive epidemiological study of the characteristics, treatments and outcomes of patients with incident DM.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods</jats:title>\n                    <jats:p>This retrospective study identified two DM inception cohorts using (1) commercial claims and (2) electronic health record (EHR) data from the Excellence Network in Rheumatology to Innovate Care and High-impact research (ENRICH), a community rheumatology practice-based research network. Patient characteristics, treatments and healthcare utilisation were assessed using the 18 months before and 12 months after diagnosis in claims and the 12 months before and after diagnosis in EHR data.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results</jats:title>\n                    <jats:p>We identified 2475 patients (claims) and 1196 patients (EHR) with incident DM. Among 998 patients in the EHR cohort with available laboratory data, 472 had available myositis panel results, with 165 (35.0%) having a positive myositis-specific antibody. Glucocorticoid use was common, 68.7% and 73.8% in the two cohorts, respectively, with initial doses most often &gt;20 mg/day; among glucocorticoid users, mean cumulative dose was 1407 mg in the claims cohort. Hydroxychloroquine, methotrexate and mycophenolate were the most commonly used immunomodulatory therapies. During follow-up in the claims data cohort, incidence per 1000 person-years was 92.2, 15.3, 6.4, 2.9 and 2.1 for all-cause hospitalisation, malignancy, interstitial lung disease, gastrostomy tube placement and myocarditis, respectively.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion</jats:title>\n                    <jats:p>Administrative claims and EHR data can be leveraged to assess treatment patterns and longitudinal outcomes/disease manifestations in incident dermatomyositis cohorts. This study highlights a high burden of glucocorticoid exposure, significant heterogeneity in treatment and high healthcare utilisation in this population.</jats:p>\n                  </jats:sec>","journal":"RMD Open","year":2026,"id":628934,"datarank":0.10397207708399181,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"self_citation_contribution":0.10397207708399181,"citation_network_contribution":0.0,"self_endowment_contribution":0.10397207708399181,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1267033,"name":"Ellen Romich","orcid":"0000-0002-8233-4703","position":1,"is_corresponding":false},{"id":1503864,"name":"Thomas R Riley","orcid":null,"position":2,"is_corresponding":false},{"id":314415,"name":"Bryant R. England","orcid":"0000-0002-9649-3588","position":3,"is_corresponding":false},{"id":1628653,"name":"Shanette Daigle","orcid":null,"position":4,"is_corresponding":false},{"id":1110754,"name":"Emily E. Holladay","orcid":"0009-0002-1811-6602","position":5,"is_corresponding":false},{"id":1239493,"name":"Yujie Su","orcid":"0000-0003-0273-8714","position":6,"is_corresponding":false},{"id":314416,"name":"Fenglong Xie","orcid":"0000-0002-7365-4801","position":7,"is_corresponding":false},{"id":1628655,"name":"Karim R Masri","orcid":null,"position":8,"is_corresponding":false},{"id":305811,"name":"Jeffrey R. Curtis","orcid":"0000-0002-8907-8976","position":9,"is_corresponding":false},{"id":305805,"name":"Michael George","orcid":"0000-0002-0398-2308","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Characteristics, treatments and outcomes of patients with dermatomyositis using real-world data","abstract":"<jats:sec>\n                    <jats:title>Objective</jats:title>\n                    <jats:p>Studies of dermatomyositis (DM) are frequently limited to single-centre cohorts. We used two large nationally representative US cohorts to conduct a descriptive epidemiological study of the characteristics, treatments and outcomes of patients with incident DM.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods</jats:title>\n                    <jats:p>This retrospective study identified two DM inception cohorts using (1) commercial claims and (2) electronic health record (EHR) data from the Excellence Network in Rheumatology to Innovate Care and High-impact research (ENRICH), a community rheumatology practice-based research network. Patient characteristics, treatments and healthcare utilisation were assessed using the 18 months before and 12 months after diagnosis in claims and the 12 months before and after diagnosis in EHR data.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results</jats:title>\n                    <jats:p>We identified 2475 patients (claims) and 1196 patients (EHR) with incident DM. Among 998 patients in the EHR cohort with available laboratory data, 472 had available myositis panel results, with 165 (35.0%) having a positive myositis-specific antibody. Glucocorticoid use was common, 68.7% and 73.8% in the two cohorts, respectively, with initial doses most often &gt;20 mg/day; among glucocorticoid users, mean cumulative dose was 1407 mg in the claims cohort. Hydroxychloroquine, methotrexate and mycophenolate were the most commonly used immunomodulatory therapies. During follow-up in the claims data cohort, incidence per 1000 person-years was 92.2, 15.3, 6.4, 2.9 and 2.1 for all-cause hospitalisation, malignancy, interstitial lung disease, gastrostomy tube placement and myocarditis, respectively.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion</jats:title>\n                    <jats:p>Administrative claims and EHR data can be leveraged to assess treatment patterns and longitudinal outcomes/disease manifestations in incident dermatomyositis cohorts. This study highlights a high burden of glucocorticoid exposure, significant heterogeneity in treatment and high healthcare utilisation in this population.</jats:p>\n                  </jats:sec>","is_dataset_classified":null,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"41592913","pmcid":"PMC12853428","openalex_id":"https://openalex.org/W7125837343","authors":[],"funders":[{"funder_name":"National Institutes of Health Pharmacoepidemiology","grant_id":"5T32GM075766-17","title":null},{"funder_name":"U.S. Department of Veterans Affairs CSR&D","grant_id":"IK2 CX002203","title":null},{"funder_name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","grant_id":"P30AR072583","title":null},{"funder_name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","grant_id":"Rheumatology Research Training Grant T32-AR076951-","title":null},{"funder_name":"NIAMS NIH HHS","grant_id":"T32 AR076951","title":null},{"funder_name":"NIGMS NIH HHS","grant_id":"T32 GM075766","title":null},{"funder_name":"Rheumatology Research Foundation","grant_id":"","title":null},{"funder_name":"Pfizer","grant_id":"","title":null}],"total_grants":8,"fwci":7.621,"citation_percentile":0.93254799,"influential_citations":0,"citation_trend":[{"year":2026,"count":1}],"oa_status":"gold","license":"cc-by-nc","oa_locations":[{"url":"https://rmdopen.bmj.com/content/12/1/e006356.full.pdf","host_type":"journal"},{"url":"https://rmdopen.bmj.com/content/12/1/e006356.full.pdf","host_type":"publisher"},{"url":"https://syndication.highwire.org/content/doi/10.1136/rmdopen-2025-006356","host_type":"publisher"},{"url":"https://doi.org/10.1136/rmdopen-2025-006356","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/41592913","host_type":"repository"},{"url":"https://doaj.org/article/af129113eb93491cbadf2fe1d6bd49dc","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12853428","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12853428/","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC12853428","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC12853428?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Inflammatory Myopathies and Dermatomyositis","Rheumatoid Arthritis Research and Therapies","Spondyloarthritis Studies and Treatments","Humans","Dermatomyositis","Female","Male","Retrospective Studies","Middle Aged","Adult","Treatment Outcome","Aged","Glucocorticoids","Electronic Health Records","United States"],"mesh_terms":["Adult","Aged","Dermatomyositis","Female","Glucocorticoids","Humans","Hydroxychloroquine","Male","Methotrexate","Middle Aged","Retrospective Studies","United States","Treatment Outcome","Electronic Health Records"],"keywords":["Dermatomyositis","Glucocorticoid","MEDLINE","Connective tissue disease","Longitudinal data","Patient data","Health care","Epidemiology","Glucocorticoids","Treatment","Lung Diseases, Interstitial"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-05T15:38:46.347978Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}